Acceleron Pharma, Inc.

128 Sidney Street

Cambridge, MA  02139

Tel: 617.649.9200


Leadership:
John Knopf, Ph.D.
CEO & Founder


Website:
www.acceleronpharma.com


Information:
info@acceleronpharma.com

Acceleron Pharma, Inc.

Flagship Partners:  Ed Kania
Initial Investment: 
2004
Status: 
Public

Acceleron (NASDAQ: XLRN) is a publicly traded clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases. Ed Kania is on the Board of Directors.